Erythropoietin suppresses the formation of macrophage foam cells: Role of liver X receptor α

Circulation

Volumn 121, Issue 16, 2010, Pages 1828-1837

  Lu, Kuo Yun ^a   Ching, Li Chieh ^a   Su, Kuo Hui ^a   Yu, Yuan Bin ^b   Kou, Yu Ru ^a   Hsiao, Sheng Huang ^c   Huang, Yu Chu ^a   Chen, Chien Yu ^a   Cheng, Li Ching ^d   Pan, Ching Chian ^a   Lee, Tzong Shyuan ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Atherosclerosis; Cholesterol; Leukocytes; Lipoproteins

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; APOLIPOPROTEIN E; CD36 ANTIGEN; ERYTHROPOIETIN; LIVER X RECEPTOR ALPHA; OXIDIZED LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR A; SCAVENGER RECEPTOR BI; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; FOAM CELL; HEART PROTECTION; HEMATOPOIESIS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR UPREGULATION;

ANIMALS; ANTIGENS, CD36; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CARDIOTONIC AGENTS; CELLS, CULTURED; ERYTHROPOIETIN; FOAM CELLS; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, LDL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; ORPHAN NUCLEAR RECEPTORS; RNA, MESSENGER; SCAVENGER RECEPTORS, CLASS A; SCAVENGER RECEPTORS, CLASS B;

EID: 77951769190     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.876839     Document Type: Article

References (40)

1. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in athero-genesis. Free Radic Biol Med. 1996;20:707-727.
2. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104: 503-516.
3. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
4. Witztum JL. You are right too! J Clin Invest. 2005;115:2072-2075.
5. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, Rhee JS, Silverstein R, Hoff HF, Freeman MW. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem. 2002;277:49982-49988. (Pubitemid 36014449)
6. Rahaman SO, Lennon DJ, Febbraio M, Podrez EA, Hazen SL, Silverstein RL. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab. 2006;4:211-221. (Pubitemid 44283954)
7. Van Eck M, Bos IS, Hildebrand RB, Van Rij BT, Van Berkel TJ. Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development. Am J Pathol. 2004;165:785-794. (Pubitemid 39129286)
8. Joyce CW, Amar MJ, Lambert G, Vaisman BL, Paigen B, Najib-Fruchart J, Hoyt RFJ, Neufeld ED, Remaley AT, Fredrickson DS, Brewer HBJ, Santamarina-Fojo S. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci USA. 2002;99:407-412. (Pubitemid 34060374)
9. Out R, Hoekstra M, Hildebrand RB, Kruit JK, Meurs I, Li Z, Kuipers F, Van Berkel TJ, Van Eck M. Macrophage ABCG1 deletion disrupts lipid homeostasis in alveolar macrophages and moderately influences atherosclerotic lesion development in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26:2295-2300. (Pubitemid 44465725)
10. Gerbod-Giannone MC, Li Y, Holleboom A, Han S, Hsu LC, Tabas I, Tall AR. TNFalpha induces ABCA1 through NF-KB in macrophages and in phagocytes ingesting apoptotic cells. Proc Natl Acad Sci USA. 2006; 103:3112-3117. (Pubitemid 43346433)
11. de Villiers WJ, Fraser IP, Gordon S. Cytokine and growth factor regulation of macrophage scavenger receptor expression and function. Immunol Lett. 1994;43:73-79.
12. Liu Y, Li D, Chen J, Xie J, Bandyopadhyay S, Zhang D, Nemarkommula AR, Liu H, Mehta JL, Hermonat PL. Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10. Atherosclerosis. 2006;188:19-27. (Pubitemid 44160702)
13. Fazio S, Linton MF. The inflamed plaque: cytokine production and cellular cholesterol balance in the vessel wall. Am J Cardiol. 2001;88: 12E-15E.
14. Stohlman F Jr, Ebbe S, Morse B, Howard D, Donovan J. Regulation of erythropoiesis: kinetics of red cell production. Ann N Y Acad Sci. 1968; 149:156-172.
15. Schooley JC, Garcia JF. Immunologic studies on the mechanism of action of erythropoietin. Proc Soc Exp Biol Med. 1962;110:636-641.
16. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA. 2005;293:90-95. (Pubitemid 40066704)
17. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, Nico B, Roncali L, Dammacco F. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood. 1999;93:2627-2636. (Pubitemid 29181195)
18. Rich IN, Vogt C, Pentz S. Erythropoietin gene expression in vitro and in vivo detected by in situ hybridization. Blood Cells. 1988;14:505-520. (Pubitemid 19239260)
19. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, Talan MI. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA. 2003;100:11612-11617. (Pubitemid 37205984)
20. Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox-Talbot K, Lu H, Zweier JL, Semenza GL. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation. 2003;108:79-85. (Pubitemid 36859024)
21. Urao N, Okigaki M, Yamada H, Aadachi Y, Matsuno K, Matsui A, Matsunaga S, Tateishi K, Nomura T, Takahashi T, Tatsumi T, Matsubara H. Erythropoietin- mobilized endothelial progenitors enhance reendothe-lialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res. 2006;98:1405-1413. (Pubitemid 43948065)
22. Buemi M, Allegra A, Corica F, Calapai G, Cavallaro G, Aloisi C, Pettinato G, Russo A, Frisina N. Does erythropoietin administration affect progression of atherosclerosis in Watanabe heritable hyperlipaemic rabbits? Nephrol Dial Transplant. 1998;13:2706-2708. (Pubitemid 28445909)
23. Siamopoulos KC, Gouva C, Katopodis KP, Tzallas C, Nikolopoulos P, Papavasiliou EC, Tselepis AD. Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKD. Am J Kidney Dis. 2006;48:242-249. (Pubitemid 44051724)
24. Pawlak K, Pawlak D, Mysliwiec M. Long-term erythropoietin therapy decreases CC-chemokine levels and intima-media thickness in hemo-dialyzed patients. Am J Nephrol. 2006;26:497-502. (Pubitemid 44971742)
25. Mbalaviele G, Abu-Amer Y, Meng A, Jaiswal R, Beck S, Pittenger MF, Thiede MA, Marshak DR. Activation of peroxisome proliferator-acti-vated receptor-gamma pathway inhibits osteoclast differentiation. J Biol Chem. 2000;275:14388-14393. (Pubitemid 30339723)
26. Wang LJ, Lee TS, Lee FY, Pai RC, Chau LY. Expression of heme oxygenase-1 in atherosclerotic lesions. Am J Pathol. 1998;152:711-720. (Pubitemid 28110718)
27. 2. J Biol Chem. 2003;278: 19325-19330.
28. Buemi M, Galeano M, Sturiale A, Ientile R, Crisafulli C, Parisi A, Catania M, Calapai G, Impala P, Aloisi C, Squadrito F, Altavilla D, Bitto A, Tuccari G, Frisina N. Recombinant human erythropoietin stimulates angiogenesis and healing of ischemic skin wounds. Shock. 2004;22: 169-173. (Pubitemid 40228196)
29. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res. 2008;79: 360-376.
30. Shatrov VA, Sumbayev VV, Zhou J, Brune B. Oxidized low-density lipoprotein (oxLDL) triggers hypoxia-inducible factor-1a (HIF-1a) accumulation viaredox-dependent mechanisms. Blood. 2003;101:4847-4849. (Pubitemid 36857745)
31. McNeish J, Aiello RJ, Guyot D, Turi T, Gabel C, Aldinger C, Hoppe KL, Roach ML, Royer LJ, de Wet J, Broccardo C, Chimini G, Francone OL. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad Sci USA. 2000;97:4245-4250. (Pubitemid 30226118)
32. Trigatti B, Rayburn H, Vinals M, Braun A, Miettinen H, Penman M, Hertz M, Schrenzel M, Amigo L, Rigotti A, Krieger M. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci USA. 1999;96:9322-9327. (Pubitemid 29374753)
33. Kennedy MA, Barrera GC, Nakamura K, Baldan A, Tarr P, Fishbein MC, Frank J, Francone OL, Edwards PA. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 2005;1:121-131. (Pubitemid 43977167)
34. Rubic T, Lorenz RL. Downregulated CD36 and oxLDL uptake and stimulated ABCA1/G1 and cholesterol efflux as anti-atherosclerotic mechanisms of interleukin-10. Cardiovasc Res. 2006;69:527-535. (Pubitemid 43098809)
35. Panousis CG, Zuckerman SH. Interferon-gamma induces downregulation of Tangier disease gene ATP-binding-cassette transporter 1 in macro-phage-derived foam cells. Arterioscler Thromb Vasc Biol. 2000;20: 1565-1571.
36. Khovidhunkit W, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: differential role of LXR. J Lipid Res. 2003;44:1728-1736. (Pubitemid 37185884)
37. Chen M, Li W, Wang N, Zhu Y, Wang X. ROS and NF-kappaB but not LXR mediate IL-1beta signaling for the downregulation of ATP-binding cassette transporter A1. Am J Physiol Cell Physiol. 2007;292: C1493-C1501. (Pubitemid 46631729)
38. Tian L, Luo N, Klein RL, Chung BH, Garvey WT, Fu Y. Adiponectin reduces lipid accumulation in macrophage foam cells. Atherosclerosis. 2009;202:152-161.
39. Beyea MM, Heslop CL, Sawyez CG, Edwards JY, Markle JG, Hegele RA, Huff MW. Selective up-regulation of LXR-regulated genes ABCA1, ABCG1, and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol. J Biol Chem. 2007;282:5207-5216.
40. Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, Chen M, Noh G, Goodman J, Hagger GN, Tran J, Tippin TK, Wang X, Lusis AJ, Hsueh WA, Law RE, Collins JL, Willson TM, Tontonoz P. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA. 2002;99:7604-7609. (Pubitemid 34568738)